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Abstract 
The Virus-Serum-Toxin Act of 1913 provides the legal basis for the regulation of veterinary biological products in the United 
States, and the USDA’s Center for Veterinary Biologics (CVB) has the authority to issue licenses and permits for such products. 
The law was intended to establish standards and control the importation of products into the United States as well as the domestic 
distribution of products, assuring the purity, safety, potency, and efficacy of veterinary biological products. Prelicensing data 
evaluation procedures are designed to assess the quality of each product and support product label claims. Under the standard 
licensing process, this spectrum of evaluation includes complete characterization of seed material and ingredients, and 
laboratory- and host-animal safety and efficacy studies. Post-license testing includes batch tests for purity, safety, and potency. 
As part of the production and testing of regulated products, procedures involving animals are used to validate product 
requirements for safety, potency, and efficacy. Incorporating alternative methods to reduce, refine, and replace the use of animals 
in the development and testing of veterinary biological products has been a strategic goal for the CVB for several decades, and 
current licensing processes and policies are designed to support and encourage the shift from animal-based methods to alternative 
practices while ensuring that regulated products continue to be safe and effective. 
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1. Regulatory framework and biological product definition 
The Virus-Serum-Toxin Act of 1913 (21 U.S.C. 151-159) [1] provides the legal basis for the regulation of 
veterinary biological products in the United States, and the USDA Center for Veterinary Biologics (CVB) has the 
regulatory authority to issue licenses and permits for such products. The law was amended in 1985 by the Food 
Security Act to include the distribution of all veterinary biological products (both interstate and intrastate) in the 
United States, as well as those intended for export [2]. Administrative regulations and standards appear in Title 9 of 
the U.S. Code of Federal Regulations (CFR) Parts 101-122 [3] with additional program guidance found in CVB 
Notices, Veterinary Services Memoranda, General Licensing Considerations, and other guidance documents. 
Veterinary biological products are defined in 9 CFR 101.2 as “all viruses, serums, toxins (excluding substances that 
are selectively toxic to microorganisms; e.g., antibiotics), or analogous products at any stage of production, 
shipment, distribution, or sale, which are intended for use in the treatment of animals and which act primarily 
through the direct stimulation, supplementation, enhancement, or modulation of the immune system or immune 
response.” This includes but is not limited to “vaccines, bacterins, allergens, antibodies, antitoxins, toxoids, 
immunostimulants, certain cytokines, antigenic or immunizing components of live organisms, and diagnostic 
components, that are of natural or synthetic origin, or that are derived from synthesizing or altering various 
substances or components of substances such as microorganisms, genes or genetic sequences, carbohydrates, 
proteins, antigens, allergens, or antibodies”. 
2. Key licensing requirements  
Prelicensing data evaluation procedures are designed to assess the purity, safety, potency, and effectiveness of 
each product and to support all product label claims. In order to fulfill these criteria, data from all phases of product 
development are evaluated against these key elements. This spectrum of evaluation includes complete 
characterization and identification of seed material and ingredients, laboratory and host animal safety and efficacy 
studies, and stability and monitoring of field performance. General purity, safety, potency, and efficacy 
requirements [3] are as follows:  
Purity. All product components and ingredients must meet standards of purity and quality. Master Seeds, Master 
Cell Stocks, Primary Cells, ingredients of animal origin, and final products must be tested and shown to be free of 
extraneous microorganisms. Eggs used in the production of biological products must be acquired from specific-
pathogen-free flocks. Purity and identification of Master Seeds and Master Cells are confirmed by testing at the 
CVB. In addition to the first serials (batches of completed product) prepared under license, random samples of 
serials are subjected to prerelease purity testing at the CVB to verify manufacturers’ quality assurance/quality 
control of completed product. 
Safety. Products must be shown to be safe through a combination of safety evaluations. Master Seeds and Master 
Cell Stocks must be fully identified and characterized. Production passage levels (limits) are established for seeds 
and cells. Master Seeds for live products are tested for shed and spread and reversion to virulence through 
backpassage studies in the host animal. Following a minimum of five passages in the host (10 for poultry), 
recovered isolates are fully characterized using the same procedures that were used for the Master Seed. 
Demonstration of an acceptable level of attenuation must be shown.  
Other safety studies are required as appropriate (e.g., use in pregnant animals, environmental safety, or adjuvants 
in products for food-producing animals). Field safety studies designed to detect unexpected reactions that may not 
have been detected in product development are required before licensure. Host-animal tests are conducted at a 
variety of geographical sites using large numbers of susceptible animals representing all ages and husbandry 
practices for which the product is intended. Final products are subjected to safety testing primarily through in vivo 
animal tests.  
Efficacy. All products must be shown to be effective according to the claims indicated on the label. Efficacy and 
product immunogenicity are almost always demonstrated by statistically valid host animal vaccination-challenge 
studies. The following general considerations are applied to efficacy studies: 
• Immunogenicity studies must be conducted using minimum levels of antigen at the highest passage level from 
the Master Seed that is permitted for production. 
• Product must be prepared in production facilities on a scale representative of normal production. 
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• Challenge methods and criteria for evaluating protection will vary with the immunizing agent but, in general, 
tests are conducted under controlled conditions using seronegative animals of the youngest age recommended on 
the label. 
• Duration of immunity data is required for some existing products (e.g., rabies vaccines) and for all newly 
licensed antigens. 
• Field efficacy studies may be considered where laboratory animal challenge models are not well established. 
Similarly, serologic data may be used to establish efficacy only when serology is indicative of protection. 
• Data is required for each species for which the product is recommended and for each route, dose, and regimen of 
administration. 
• For products with two or more fractions (components), data demonstrating there is no interference is required. 
• Stability studies are required to set the expiration date on the label. 
• Potency tests correlated to host animal vaccination and designed to measure the relative strength of each serial 
must be developed before licensure. In addition, each serial shall be formulated and tested prior to marketing to 
ensure effectiveness and reproducibility of activity (potency) according to standards set at the time of licensing. 
Generally, this is accomplished through established laboratory animal or in vitro minimum potency levels using 
microbiological counts or virus titrations. 
3. Comprehensive product evaluation  
Licensing data should be developed and submitted for licensure in a logical sequence representing successive 
steps in product development (e.g., Master Seed purity and identity, laboratory safety, immunogenicity, initial 
production serials [usually three consecutive serials to demonstrate consistency], purity, safety, potency testing, and 
field safety). All data generated in product development is required to be reported to the CVB.  Following receipt 
and evaluation of the purity, safety, potency and efficacy data described above, products are eligible for licensure. 
Additional steps (not described here) include approval of labeling, confirmatory tests, prelicense inspection, and 
production method approval.  
The procedures reviewed above provide a regulatory framework and outline general purity, safety, and efficacy 
requirements for licensing of all products. Supplementary procedures may be required for nonconventional products 
(e.g., environmental impact studies for products prepared with live recombinant microorganisms). While many 
prelicense and product testing studies require the use of animals, the application of alternative methods (e.g., 
vaccination/serology) using reduce, refine, and replace (3Rs) principles has long been encouraged and promoted as 
long as product quality is not compromised.  
4. Application of 3Rs principles 
A historical review of regulatory requirements and guidelines provides evidence of the changes that have been 
put in place in recent decades to promote animal use alternatives and application of 3Rs principles in veterinary 
biological products. Many of the standard requirements found in the 9 CFR were first established when animal-
based tests were the norm. Regulations were first published in 1969 [4] to allow for in vitro quantification of live 
viral products in lieu of animal testing. These regulations, along with the introduction and application of the Master 
Seed Lot concept initiated the shift from host-animal to laboratory-animal testing paradigms and led to the 
development of many of the current 9 CFR Standard requirements. In 1984, regulations were issued for serial 
release of bacterial and other products [5]. The CVB continues to promote the evolution from animal-based tests to 
alternative in vitro laboratory-based methodologies for assessing relative serial potency. Table 1 provides a brief 
history of the types of regulations and guidance documents that have been put in place to advance this shift. Of note 
are CVB Notices 07-02 and 07-12, which outline recent advances in validating methods for qualification of 
Leptospirae products for dogs. [6]. Regulations and guidance documents have also been published to provide 
provisions for the use of humane endpoints [7,8], which has had a significant impact on the animals used in the 
testing of veterinary biological products. 
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Table 1. Example regulations and guidance documents related to in vitro and reduce, refine, replace 
initiatives 
 
Document Title/Topic Date of Changea 
9 CFR 113.8 In vitro tests for Serial Release May 21, 1984 
SAM 120 Supplemental Assay Method (SAM) for In vitro Potency Testing of Bovine 
Respiratory Viruses 
November 1, 1991 
SAM 318 Relative Potency Methods for Enzyme Immunoassays July 17, 1992 
SAM 620-623 Potency Testing for Enterotoxigenic Escherichia Coli Bacterins April 15, 1992 to 
June 11, 1993 
SAM 321 Quantitating the GP70 Antigen Feline Leukemia Virus April 1, 1994 
9 CFR 117.4 Test Animals (allow for humane removal) August 21, 1995 
SAM 322 Specific Viral Antigen Content in Inactivated Canine Coronavirus Vaccine October 24, 1997 
VS Memo 800.90 Guidelines for Veterinary Biologics Relative Potency Assays and Reference 
Preparations Based on ELISA Antigen Quantification 
August 5, 1998 
SAM 624-627 In vitro Potency Testing for Leptospira Bacterins (Leptospira interrogans serovars 
pomona, canicola, grippotyphosa, and icterohaemorrhagiae) 
August 30, 2000 
VS Memo 800.99 In vitro Relative Potency Tests of Inactivated Bovine Rhinotracheitis Vaccine April 26, 2001 
VS Memo 800.102 Exemption from Leptospira Bacterin Testing Under 9 CFR 113.101(c), 113.102(c), 
113.103(c), and 113.104(c) 
May 23, 2002 
VS Memo 800.104 In vitro Serial Release Potency Test for Completed Product Containing Clostridium 
chauvoei 
May 29, 2003 
CVB Notice 04-09 Use of Humane Endpoints in Animal Testing of Biologic Products April 1, 2004 
CVB Notice 04-17 Exemption to 3-year Master Seed Immunogenicity Retesting November 4, 2004 
Draft VS Memo Qualification and Requalification of References by Serology October 2, 2006 
CVB Notice 07-02 Qualification of Leptospira grippotyphosa and icterohaemorrhagiae Reference 
Bacterins for Products Intended for Use in Dogs 
March 1, 2007 
CVB Notice 07-12 Qualification of Leptospira Pomona and Leptospira canicola Reference Bacterins for 
Products Intended for Use in Dogs 
July 13, 2007 
Draft VS Memo Guidelines for Live Master References May 30, 2008 
Draft VS Memo Bovine Coronavirus and Rotavirus Reference Qualification by Colostral Antibody 
Titers 
May 30, 2008 
VS Memo 800.112 Guidelines for Validation of In vitro Potency Assays June 25, 2008 
CVB Notice 09-16 Qualification of Leptospira Canicola, Leptospira Grippotyphosa, Leptospira 
Icterohaemorrhagiae, and Leptospira Pomona Reference Bacterins for Products 
Intended for Use in Swine and/or Cattle 
August 3, 2009 
SAM 613 In vitro Potency Testing of Erysipelothrix rhusiopathiae Bacterins Dec. 29, 2009 
VS Memo 800.112 Addendum specific to ELISA method validation Anticipated in 2011 
Abbreviations: CFR = Code of Federal Regulations; CVB = USDA Center for Veterinary Biologics; SAM = Supplemental Assay Method; 
VS = Veterinary Services 
aDate may vary slightly based on version control of documents. 
 
4.1. Challenges and goals 
Although progress has been made in the application of the 3Rs principles to veterinary biologics testing and 
approval processes, many challenges remain. Applying and converting licensing standards for products that were 
licensed before the advent of new technologies requires a large investment in both time and resources to ensure that 
correlation to protection is still demonstrated. Application of in vitro methods to quantify potency often requires 
identifying specific protective antigens, which in many cases is unknown or not possible. Validating new techniques 
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and technologies often requires considerable effort to ensure that the new potency test is a true correlate to 
protection. Considering the vast array of veterinary biological products that are currently licensed for hundreds of 
different animal diseases, it is apparent that considerable effort will be required to move this initiative along for the 
entire spectrum of available products.  
Through changes in policy and procedure, the CVB continually looks for ways to require fewer animals in tests 
associated with regulatory approvals. This is a goal shared by all, and the best way to achieve this goal is through a 
collaborative effort with academia and industry to develop science-based methods within a regulatory framework 
that is flexible without compromising proprietary information that individual companies may not be willing to share 
publically. Research and development incentives are also needed to address knowledge gaps and accelerate the 
development of new and alternative methods for both existing products and products under development. 
International harmonization of standards and regulatory requirements regarding the use of animal will also provide 
impetus for broader acceptance and use of alternative methods.  
5. Summary 
The USDA promotes and encourages the development, validation, and regulatory acceptance of new methods 
while ensuring the purity, safety, potency, and efficacy of veterinary biological products. The CVB is committed to 
considering alternative approaches and interacting with stakeholders to better utilize and implement new 
technologies and alternatives to reduce, refine, and replace the use of animals in the production and testing of 
veterinary biologics.  
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